CLAIMS

1. A pharmaceutical formulation for an antigen binding protein comprising:

a. about 150 to 250 mg/mL antigen binding protein;

b. about 1 to 100 mM of a buffering agent providing a pH of 6.0±0.5;

c. about 90 to 150 mM of a tonicity agent;

d. about 1 to 100 mM of a stabilizer; and

e. about 0.005 to 0.015% (w/v) of a nonionic surfactant;

wherein the antigen binding protein comprises amino acid sequences CDRH1 of SEQ ID NO:11, CDRH2 of SEQ ID NO: 12, CDRH3 of SEQ ID NO:13, CDRL1 of SEQ ID NO:14, CDRL2 of SEQ ID NO:15, and CDRL3 of SEQ ID NO:16.

2. The pharmaceutical formulation according to claim 1, wherein said antigen binding protein is a monoclonal antibody or fragment thereof.

3. The pharmaceutical formulation according to claim 2, wherein said monoclonal antibody or fragment thereof binds to BLyS (SEQ ID NO: 1) or a hetero- or homo-trimeric form of BLyS.

4. The pharmaceutical formulation according to claim 2 or 3, wherein said monoclonal antibody comprises heavy and light chain variable regions comprising amino acid sequences that are 90% identical to SEQ ID NOs: 2 and 3, respectively.

5. The pharmaceutical formulation according to any one of claims 2-4, wherein said monoclonal antibody comprises heavy and light chains comprising amino acid sequences that are 90% identical to SEQ ID NOs: 6 and 7, respectively.

6. The pharmaceutical formulation according to any one of claims 2-5, wherein the monoclonal antibody concentration is 200±20 mg/mL.

7. The pharmaceutical formulation according to any one of claims 1-6, wherein the tonicity agent is sodium chloride.

8. The pharmaceutical formulation according to claim 7, wherein the sodium chloride concentration is 115±10 mM.

9. The pharmaceutical formulation according to any one of claims 1-8, wherein the buffering agent is histidine.

10. The pharmaceutical formulation according to claim 9, wherein the histidine concentration is about 5 to 15 mM.

11. The pharmaceutical formulation according to claim 10, wherein the histidine concentration is 10±2 mM.

12. The pharmaceutical formulation according to any one of claims 1-11, wherein the stabilizer is arginine.

13. The pharmaceutical formulation according to claim 12, wherein the arginine concentration is about 20 to 30 mM.

14. The pharmaceutical formulation according to claim 13, wherein the arginine concentration is 25±2 mM.

15. The pharmaceutical formulation according to any one of claims 1-14, wherein the nonionic surfactant is polysorbate 80.

16. The pharmaceutical formulation according to claim 15, wherein the polysorbate 80 concentration is about 0.01% (w/v).

17. The pharmaceutical formulation according to any one of claims 1-16 which is stable upon freezing and thawing.

18. The pharmaceutical formulation according to any one of claims 1-17 for subcutaneous or intramuscular administration.